Steven A Kaplan

List of Publications by Year
in descending order

113 papers	7,592 citations	117619 34 h-index	51602 86 g-index
121 all docs	121 docs citations	121 times ranked	4829 citing authors

#	Article	IF	Citations
1	The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. New England Journal of Medicine, 2003, 349, 2387-2398.	27.0	1,780
2	Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. Journal of Urology, 2011, 185, 1793-1803.	0.4	946
3	Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer. Journal of Urology, 1992, 147, 815-816.	0.4	669
4	Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder. JAMA - Journal of the American Medical Association, 2006, 296, 2319.	7.4	472
5	Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a Î²3-Adrenoceptor Agonist, in Overactive Bladder. European Urology, 2013, 63, 296-305.	1.9	301
6	Benign prostatic hyperplasia. Nature Reviews Disease Primers, 2016, 2, 16031.	30.5	223
7	Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction. European Urology, 2007, 51, 1717-1723.	1.9	207
8	Bladder and Sphincter Behavior in Patients With Spinal Cord Lesions. Journal of Urology, 1991, 146, 113-117.	0.4	174
9	Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART Iâ€"Initial Work-up and Medical Management. Journal of Urology, 2021, 206, 806-817.	0.4	165
10	The Age Related Decrease in Testosterone is Significantly Exacerbated in Obese Men With the Metabolic Syndrome. What are the Implications for the Relatively High Incidence of Erectile Dysfunction Observed in These Men?. Journal of Urology, 2006, 176, 1524-1528.	0.4	155
11	Urinary Retention and Post-Void Residual Urine in Men: Separating Truth From Tradition. Journal of Urology, 2008, 180, 47-54.	0.4	137
12	Combination Therapy With Doxazosin and Finasteride for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptoms and a Baseline Total Prostate Volume of 25 Ml or Greater. Journal of Urology, 2006, 175, 217-220.	0.4	136
13	Safety and Tolerability of Solifenacin Add-on Therapy to Î±-Blocker Treated Men With Residual Urgency and Frequency. Journal of Urology, 2009, 182, 2825-2830.	0.4	109
14	Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, headâ€toâ€head, placeboâ€controlled trial. BJU International, 2011, 107, 1432-1440.	2.5	97
15	Role of inflammation in benign prostatic hyperplasia. Reviews in Urology, 2011, 13, 147-50.	0.9	80
16	Solifenacin Plus Tamsulosin Combination Treatment in Men With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction: A Randomized Controlled Trial. European Urology, 2013, 63, 158-165.	1.9	78
17	Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology, 2006, 68, 328-332.	1.0	77
18	1277: The Impact of Acute or Chronic Inflammation in Baseline Biopsy on the Risk of Clinical Progression of BPH: Results from the MTOPS Study. Journal of Urology, 2005, 173, 346-346.	0.4	74

#	Article	IF	Citations
19	Urological Neurology and Urodynamics: Urodynamics and the Etiology of Post-Prostatectomy Urinary Incontinence: The Initial Columbia Experience. Journal of Urology, 1995, 153, 1034-1037.	0.4	72
20	Extendedâ€•release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU International, 2008, 102, 1133-1139.	2.5	71
21	TheÂmolecular biology of prostate cancer: current understanding and clinical implications. Prostate Cancer and Prostatic Diseases, 2018, 21, 22-36.	3.9	70
22	Addâ€•on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving Î±â€•blocker treatment for lower urinary tract symptoms. BJU International, 2012, 109, 1831-1840.	2.5	59
23	Long-Term Treatment With Finasteride Results in a Clinically Significant Reduction in Total Prostate Volume Compared to Placebo Over the Full Range of Baseline Prostate Sizes in Men Enrolled in the MTOPS Trial. Journal of Urology, 2008, 180, 1030-1033.	0.4	58
24	Systematic review and metaâ€•analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. International Journal of Urology, 2018, 25, 196-205.	1.0	55
25	WATER II (80â€“150 mL) procedural outcomes. BJU International, 2019, 123, 106-112.	2.5	53
26	PCPT: Evidence That Finasteride Reduces Risk of Most Frequently Detected Intermediate- and High-grade (Gleason Score 6 and 7) Cancer. Urology, 2009, 73, 935-939.	1.0	51
27	Laser Vaporization of the Prostate With the 180-W XPS-Greenlight Laser in Patients With Ongoing Platelet Aggregation Inhibition and Oral Anticoagulation. Urology, 2016, 91, 167-173.	1.0	49
28	Safety and Tolerability of Solifenacin Add-on Therapy to Î±-Blocker Treated Men With Residual Urgency and Frequency. Journal of Urology, 2013, 189, S129-34.	0.4	45
29	Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male, 2013, 16, 169-172.	1.9	43
30	Long-Term Treatment With Finasteride Improves Clinical Progression of Benign Prostatic Hyperplasia in Men With an Enlarged Versus a Smaller Prostate: Data From the MTOPS Trial. Journal of Urology, 2011, 185, 1369-1373.	0.4	41
31	Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results. Urology, 2019, 129, 1-7.	1.0	38
32	Aquablation for benign prostatic hyperplasia in large prostates (80â€“150 mL): 6â€•month results from the <scp>WATER II</scp> trial. BJU International, 2019, 124, 321-328.	2.5	38
33	Rezum therapy for patients with large prostates (â‰¥â€‰80Âg): initial clinical experience and postoperative outcomes. World Journal of Urology, 2021, 39, 3041-3048.	2.2	38
34	Use and risks of surgical mesh for pelvic organ prolapse surgery in women in New York state: population based cohort study. BMJ, The, 2015, 350, h2685-h2685.	6.0	37
35	Central obesity is predictive of persistent storage lower urinary tract symptoms (<scp>LUTS</scp>) after surgery for benign prostatic enlargement: results of a multicentre prospective study. BJU International, 2015, 116, 271-277.	2.5	37
36	Relationship Between Depression and Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Reviews in Urology, 2015, 17, 51-7.	0.9	37

#	Article	IF	Citations
37	Trends and Utilization of Laser Prostatectomy in Ambulatory Surgical Procedures for the Treatment of Benign Prostatic Hyperplasia in New York State (2000â€“2011). Journal of Endourology, 2015, 29, 700-706.	2.1	35
38	Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). Journal of Urology, 2020, 203, 1163-1171.	0.4	35
39	Seminal Vesicle Urinary Reflux as a Complication of Transurethral Resection of Ejaculatory Ducts. Journal of Urology, 1995, 153, 1234-1235.	0.4	33
40	Incorporation of a Stress Reducing Mobile App in the Care of Patients With Type 2 Diabetes: A Prospective Study. JMIR MHealth and UHealth, 2017, 5, e75.	3.7	31
41	Incidental Prostate Cancer in Transurethral Resection of the Prostate Specimens in the Modern Era. Advances in Urology, 2014, 2014, 1-4.	1.3	30
42	PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study. Urology, 2002, 60, 464-468.	1.0	29
43	Prostate Biopsy in Response to a Change in Nadir Prostate Specific Antigen of 0.4 ng/ml after Treatment with 5Î±-Reductase Inhibitors Markedly Enhances the Detection Rate of Prostate Cancer. Journal of Urology, 2012, 188, 757-761.	0.4	28
44	Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU International, 2009, 103, 48-57.	2.5	27
45	Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Aging Male, 2010, 13, 100-107.	1.9	25
46	Modern best practice in the management of benign prostatic hyperplasia in the elderly. Therapeutic Advances in Urology, 2020, 12, 175628722092948.	2.0	24
47	National study of utilization of male incontinence procedures. Neurourology and Urodynamics, 2016, 35, 74-80.	1.5	23
48	Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. Journal of Urology, 2016, 195, 1825-1829.	0.4	23
49	The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Translational Andrology and Urology, 2017, 6, 295-304.	1.4	23
50	Prostatic and Periprostatic Interstitial Temperature Measurements in Patients Treated with Transrectal Thermal Therapy (Local Intracavitary Microwave Hyperthermia). Journal of Urology, 1992, 147, 1562-1565.	0.4	22
51	Clinical Considerations for Intravesical Prostatic Protrusion in the Evaluation and Management of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia. Current Urology, 2018, 12, 6-12.	0.6	22
52	Disparities in the Use of Sacral Neuromodulation among Medicare Beneficiaries. Journal of Urology, 2015, 194, 449-453.	0.4	21
53	Use of prostatic stents for the treatment of benign prostatic hyperplasia in high-risk patients. Current Urology Reports, 2001, 2, 277-284.	2.2	20
54	Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual function. Urology, 2004, 63, 428-434.	1.0	20

#	Article	IF	Citations
55	Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia. Reviews in Urology, 2006, 8 Suppl 4, S10-7.	0.9	19
56	Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS). Aging Male, 2013, 16, 48-51.	1.9	18
57	Current role of Î±â€blockers in the treatment of benign prostatic hyperplasia. BJU International, 2008, 102, 3-7.	2.5	17
58	Do Patient Characteristics Predict Responsiveness to Treatment of Overactive Bladder With Antimuscarinic Agents?. Urology, 2014, 83, 1023-1029.	1.0	17
59	Detrusor Areflexia in a Patient with Myasthenia Gravis. International Journal of Urology, 1998, 5, 188-190.	1.0	16
60	Ejaculatory Preserving Middle Lobe Onl-Transurethral Resection and Vaporization of the Prostate: 12-Year Experience. Urology, 2019, 134, 199-202.	1.0	15
61	Urinary Dysfunction in Tropical Spastic Paraparesis: Preliminary Urodynamic Survey. Journal of Urology, 1993, 150, 930-932.	0.4	14
62	Long term safety of sacral nerve modulation in medicare beneficiaries. Neurourology and Urodynamics, 2015, 34, 659-663.	1.5	14
63	BPH: Why Do Patients Fail Medical Therapy?. Current Urology Reports, 2019, 20, 40.	2.2	13
64	Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial. Journal of Clinical Medicine, 2019, 8, 1126.	2.4	12
65	National Trends and Cost of Minimally Invasive Surgery in Urology. Urology Practice, 2015, 2, 49-54.	0.5	11
66	One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases, 2021, 24, 1073-1079.	3.9	11
67	The Motion: PDE5 Inhibitors Will Have a Significant Role in the Treatment of BPH. European Urology, 2007, 52, 1523-1527.	1.9	9
68	Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone. Aging Male, 2010, 13, 40-43.	1.9	9
69	Pathologic Outcomes following Urethral Diverticulectomy in Women. Advances in Urology, 2014, 2014, 1-4.	1.3	9
70	Ejaculatory Hood-Sparing Photoselective Vaporization of the Prostate vs Bipolar Button Plasma Vaporization of the Prostate in the Surgical Management of Benign Prostatic Hyperplasia. Journal of Endourology, 2020, 34, 322-329.	2.1	9
71	Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology, 2006, 67, 225-231.	1.0	8
72	The state of TURP through a historical lens. World Journal of Urology, 2021, 39, 2255-2262.	2.2	8

#	Article	IF	Citations
73	Male Voiding Behavior: Insight from 19,824 At-Home Uroflow Profiles. Journal of Urology, 2021, 205, 1126-1132.	0.4	8
74	The endocannabinoid system, cannabis, and cannabidiol: Implications in urology and men's health. Current Urology, 2021, 15, 95-100.	0.6	8
75	Repurposing of Î±1-Adrenoceptor Antagonists: Impact in Renal Cancer. Cancers, 2020, 12, 2442.	3.7	7
76	An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. World Journal of Urology, 2021, 39, 1233-1239.	2.2	7
77	Effect of phosphodiesterase inhibitors in the bladder. Asian Journal of Urology, 2015, 2, 33-37.	1.2	6
78	Safety of Tamsulosin: A Systematic Review of Randomized Trials with a Focus on Women and Children. Drug Safety, 2018, 41, 835-842.	3.2	6
79	Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia. Current Urology Reports, 2021, 22, 5.	2.2	6
80	Identification of the patient with enlarged prostate: diagnosis and guidelines for management. Osteopathic Medicine and Primary Care, 2007, 1, 11.	0.5	5
81	Trends in surgical management and preâ€operative urodynamics in female medicare beneficiaries with mixed incontinence. Neurourology and Urodynamics, 2017, 36, 422-425.	1.5	5
82	Prostate Arterial Embolization is a Viable Option for Treating Symptoms of Benign Prostatic Hyperplasia. Journal of Urology, 2017, 198, 9-11.	0.4	5
83	The Intersection of Medicine and Urology. Medical Clinics of North America, 2018, 102, 399-415.	2.5	5
84	Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?. International Urogynecology Journal, 2019, 30, 239-244.	1.4	5
85	Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial. European Urology Focus, 2021, 7, 432-439.	3.1	5
86	Diagnosis, Evaluation, and Treatment of Mixed Urinary Incontinence in Women. Reviews in Urology, 2015, 17, 78-83.	0.9	5
87	Î±-blockade, apoptosis, and prostate shrinkage: how are they related?. Central European Journal of Urology, 2013, 66, 189-94.	0.3	5
88	The Prostate Urethral Lift: Will It Be Uplifting or Downgraded as a Treatment Strategy for Benign Prostatic Hyperplasia?. European Urology, 2015, 67, 714-715.	1.9	4
89	Bladder Outlet Obstruction and BPH. Current Bladder Dysfunction Reports, 2014, 9, 372-378.	0.5	3
90	Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms. Current Medical Research and Opinion, 2017, 33, 1731-1736.	1.9	3

#	Article	IF	Citations
91	Research Needs to Understand Self-Management of Lower Urinary Tract Symptoms: Summary of NIDDK Workshop. Journal of Urology, 2018, 199, 1408-1410.	0.4	3
92	Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results. World Journal of Urology, 2020, 38, 3101-3111.	2.2	2
93	A Tower of Babel in Todayâ€™s Urology: Disagreement in Concepts and Definitions of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Re-Treatment. Journal of Urology, 2020, 204, 213-214.	0.4	2
94	Surgical Treatment of Benign Prostatic Hyperplasiaâ€"Lift or Laser?. Urology Practice, 2014, 1, 45-48.	0.5	1
95	The Prostatic Urethral Lift Procedure: Enough Bang for the Buck?. European Urology, 2015, 68, 653-654.	1.9	1
96	Separating Opioid Fact and Fiction in Urology. Journal of Urology, 2017, 198, 990-992.	0.4	1
97	Medical Aspects of the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: 5-Alpha Reductase Inhibitors. , 2018, , 189-206.		1
98	Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men. Current Geriatrics Reports, 2019, 8, 310-314.	1.1	1
99	Editorial Comment. Journal of Urology, 2019, 202, 368-368.	0.4	1
100	Outcomes of combination therapy with daily Tadalafil 5mg plus Tamsulosin 0.4mg to treat lower urinary tract symptoms and erectile dysfunction in men with or without metabolic syndrome. Minerva Urology and Nephrology, 2020, , .	2.5	1
101	I Canâ€™t Get No Satisfaction: Patient-reported Outcomes After Different Treatment Options for Lower Urinary Tract Symptoms. European Urology Focus, 2022, 8, 377-379.	3.1	1
102	The Link Between Benign Prostatic Hyperplasia and Sexual Dysfunction. Current Bladder Dysfunction Reports, 2013, 8, 229-235.	0.5	0
103	Editorial Comment. Journal of Urology, 2017, 197, 479-479.	0.4	0
104	Editorial Comment. Urology, 2017, 110, 182.	1.0	0
105	Advances in Localized Prostate Cancer Management. BioMed Research International, 2018, 2018, 1-2.	1.9	0
106	AUTHOR REPLY. Urology, 2019, 134, 202.	1.0	0
107	Editorial Comment on: â€œImpact of Body Mass Index on Outcomes Following Anatomic GreenLight Laser Photoselective Vaporization of the Prostateâ€•by Pierce et al.. Journal of Endourology, 2021, 35, 45-46.	2.1	0
108	Reply by Authors. Journal of Urology, 2021, 205, 1132-1132.	0.4	0

#	Article	IF	Citations
109	EDITORIAL COMMENT. Urology, 2021, 153, 137-138.	1.0	0
110	IL6 Update in BPH. Japanese Journal of Urology, 2011, 102, 68-69.	0.1	0
111	SS5 BPH treatment guidelines in the US. Japanese Journal of Urology, 2011, 102, 84-85.	0.1	0
112	Reply by Authors. Journal of Urology, 2020, 203, 1171-1171.	0.4	0
113	Editorial Comment on: â€œImpact of Body Mass Index on Outcomes Following Anatomic GreenLight Laser Photoselective Vaporization of the Prostateâ€•by Pierce et al.. Journal of Endourology, 2020, , .	2.1	0